[Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer. The example of the MA-17 study].
Forciniti
Samantha
S
Ospedale Renzetti, Lanciano, CH.
D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D004967:Estrogens; D005260:Female; D050723:Fractures, Bone / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D000077289:Letrozole; D008055:Lipids / Q000097:blood; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000628:therapy; D009570:Nitriles / Q000009:adverse effects / Q000627:therapeutic use*; D015663:Osteoporosis, Postmenopausal / Q000139:chemically induced / Q000150:complications / Q000517:prevention & control; D017698:Postmenopause; D011374:Progesterone; D011788:Quality of Life; D013629:Tamoxifen / Q000627:therapeutic use*; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D004967:Estrogens; D008055:Lipids; D009363:Neoplasm Proteins; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D011374:Progesterone; D000077289:Letrozole